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O
ver the past decade, several non-vitamin K antagonist oral anticoagulants (NOACs), which selectively inhibit thrombin or activated factor X, have been developed for the anticoagulation treatment of patients with atrial fibrillation (AF). At the same time, an increasing number of systematic reviews (SRs) have been published in the field of antithrombotic treatment of AF with NOACs. This is the first effort to summarize evidence in an overview of SRs (OoSRs) focusing exclusively on AF patients. The number of SRs was compared with the number of primary randomized clinical trials (RCTs) to evaluate possible important overlap in SRs.
METHODS AND RESULTS

Data Searches and Study Selection
The authors declare that all supporting data are available within the article. This OoSRs was registered in PROSPERO (International Prospective Register of Systematic Reviews) with registration number: CRD42017078915 and was reported according to pertinent reporting guidelines for this type of study design. 1 This work constitutes an umbrella approach to identify both SRs and RCTs.
A purposive literature search for SRs and RCTs took place from inception to September 3, 2017. We searched MEDLINE (via PubMed), the Cochrane Library, and PROSPERO for SRs and clinicaltrials.gov to find further RCTs with restriction to the English language. A more comprehensive search strategy was applied in MEDLINE, using medical subject heading (Appendix I in the Data Supplement). For all included studies, reference lists were also searched. Two independent overview authors (Drs Doundoulakis and Apostolidou-Kiouti) screened the titles and abstracts against the eligibility criteria for inclusion.
We searched for SRs which compared the efficacy and safety of NOACs with warfarin in patients with AF and analyzed the full texts to extract the eligible RCTs. SRs which included observational studies were also eligible. Studies that did not use warfarin in the control group or those that included other drugs as a comparator (eg, aspirin) were excluded. Narrative reviews that did not report any search strategy and did not critically appraise the quality of included studies were also excluded. Finally, a third reviewer (Dr Antza) intervened when there was a disagreement between the other 2 authors.
Data Extraction and Quality Assessment
Two reviewers (Drs Doundoulakis and Apostolidou-Kiouti) independently extracted data/ items including citation details; objectives of the included review; type of review; participant details; setting and context; number of databases sourced and searched; date range of database searching; number of studies, types of studies and country of origin of studies included in each review; instrument used to appraise the primary studies and the rating of their quality; outcomes reported that are relevant to the OoSRs question; method of synthesis/analysis used to synthesize the evidence; major conclusions; comments or notes by the OoSRs authors; metric used and effect size (for meta-analyses); CIs (for meta-analyses). Authors were contacted in case of missing data. If the requested data could not be retrieved, the study was not included in the analysis. Two overview authors (Drs Doundoulakis and ApostolidouKiouti) independently assessed the risk of bias in the included SRs using the Risk of Bias in Systematic Reviews tool. 2 The list of RCTs was reviewed to identify overlapping studies which were included in ≥2 eligible SRs of RCTs. A citation matrix was created to depict graphically if 1 RCT was included in >1 review. The RCT of Calkins et al (Appendix III in the Data Supplement) was not included in the citation matrix, as it was published in 2017 and was not included in any SR. Three protocols from the clinicaltrials.gov were also not included (Appendix III in the Data Supplement). To quantify the overlap of primary studies included in different SRs, we calculated the measure of the corrected covered area (CCA= N c c r c
where N is the number of included publications [included double counting] in evidence synthesis [this is the sum of the ticked boxes in the citation matrix]; c is the number of RCTs and r is the number of SRs of RCTs) of overlap indicating slight (0%-5%), moderate (6%-10%), high (11%-15%), and very high (>15%) overlap. 3 Cases of dual (co)authorship were also identified in case authors of SRs had also (co)authored 1 or several of the included RCTs. 4 Moreover, an extensive check was performed to identify whether each author participated >1 SR and to analyze possible reasons.
Search Results
We found 66 SRs (Appendices II and III in the Data Supplement). All the included studies were published between 2012 and 2017 in English. Overall, 45 SRs collected their data only from RCTs, 12 from both randomized and nonrandomized studies, and 9 only from observational studies. Risk of bias of the SRs was rated as low, high, or unclear according to the Risk of Bias in Systematic Reviews tool (Appendix IV in the Data Supplement). Only one of the SRs, 5 which were included in our OoSRs, has evaluated the overall quality of evidence outcome using the Grading of Recommendations Assessments, Development, and Evaluation approach. 6 Eighteen RCTs included a total of 78 796 patients with AF, with sample sizes varying from 90 to 21 105 (Appendix V in the Data Supplement). There were no head-to-head trials. Appendix VI in the Data Supplement shows the forest plots of all SRs of RCTs with relative risk as type of metric for efficacy and safety of NOACs.
Overlap in SRs
The number of SRs which collected their data from RCTs or both from randomized and nonrandomized studies (n=57) was far greater than the number of RCTs (n=14). (Table) . With regard to dual coauthorship, 7 out of 66 of the included reviews were affected by dual (co) authorship. Of note, dual (co)authorship was not mentioned in any protocol. From the 359 authors who were included in the author lists of the publications, 1 participated in 13 SRs, 7 in 4 SRs, 1 in 3 SRs, 30 in 2 SRs, and all the others in 1 SR. We also calculated the CCA using only SRs of observational studies. In contrast to the CCA of SRs of RCTs, this was lower (CCA=10%), suggesting that the overlap of observational studies is limited.
COMMENT
Our OoSRs shows that the number of SRs for the efficacy and safety of NOACs has increased dramatically compared with the number of RCTs: a result that clearly requires a future research turn, aiming to an increase in publication of real-world studies, head-to-head RCTs or RCTs in subpopulations of AF patients, such as those undergoing ablation and cardioversion. This is the first effort to summarize evidence in an OoSRs focusing exclusively on patients with AF. Although overlap is often inevitable when results get updated based on new primary evidence, current extensive review overlap suggests that there is a waste of efforts with few RCTs covered by multiple overlapping SRs, as indicated by a high CCA of 24%. The publication of multiple reviews on the same topic has been recently discussed by Naudet et al 7 and Siontis et al. 8 According to the authors, the presentation of the same data by different independent researchers constitutes an advantage because there are publications with conflicting results on the same topic. Furthermore, new primary RCTs that emerge can be added and update previous SRs. However, the huge number of SRs composed from a small number of RCTs reflects lost effort and time because researchers usually begin the composition of data without taking into account previous SRs. In addition, authors may incorrectly select the included studies in their effort to make their SR unique, as far as the topic is concerned, and to publish their work. In the present OoSRs, there are many SRs that conclude to similar results, but there are also SRs that omit RCTs maybe in their effort to create a different publication. Table demonstrates that several SRs has omitted previously published RCTs which nonetheless were included in other SRs.
As we can see from the forest plots in Appendix VI in the Data Supplement, the question about efficacy and safety of NOACs in AF has been answered early even from the first SRs, with an exception the SRs of ablation and cardioversion in which the CIs for the relative risk of NOACc versus warfarin for stroke and major bleeding are very wide. However, a number of subsequent SRs have been published after the first ones with the aim to fill the same knowledge gap. They reported different outcomes or studied subgroups which originated from the same RCTs after adding or removing some of the RCTs. Moreover, the risk of bias of the SRs seems not to be important for the final effect size because adding or removing some RCTs seems to change a little the final outcome. This is the expected result because all RCTs are significantly in favor of the NOACs. As long as new SRs will continue to be published, the issue of overlapping will become more significant. One possible solution for this problem could be the deposit of SR protocols (eg, in PROSPERO). In this way, journals and reviewers may be able to reject quickly and easily SRs that have already been published and, thus, the publication of the same results will be avoided.
On dual coauthorship, the number 7 out of 66 may seem low, but dual (co)authorship is required to be noted in each SR because it may be a potential source of bias. Authors with dual (co)authorship may have competing interests, for instance when deciding which RCTs to include. Generally, authors may have already developed personal views about specific interventions or trials.
An important finding of the present OoSRs was that in many cases, the same author published >1 SR. Usually, 1 group of authors updated their previous publication adding a new RCT. Another strategy is the publication of an additional SR with the use of observational studies, in addition to RCTs. Additionally, there are cases of segmented publication, where the same RCTs are used, but the outcomes are modified (eg, presenting only the risk of major bleeding) or the subgroup is different (eg, including only patients with heart failure or chronic kidney disease). Finally, in some cases, the statistical analysis of the same RCTs may be different (network meta-analysis).
Limitations
We did not try to determine whether all these SRs were necessary to be published or not. This would be a subjective decision. However, publication overlap of SRs was high, and most of the recent SRs did not review the already published ones, which were similar. Some of the overlapping SRs were slices of the evidence focusing on narrow outcomes. Understanding the real merits of interventions, however, requires the full analysis of their outcomes. Thus, SRs with limited coverage of outcomes are suboptimal.
Conclusions
SRs (first level of synthesis) and OoSRs (second level of synthesis) can be considered as lenses, through which evidence from primary studies is viewed. OoSRs, a new type of publication, provides a broad evidence synthesis, highlights factors for discordant reviews, identifies knowledge gaps, biases, priorities for future research, overlap of primary research studies in each of the included research syntheses, and assesses the quality and the contemporaneity of the included reviews. From our OoSRs, it was evident that there are few RCTs covered by multiple overlapping SRs in the field of efficacy and safety of NOACs in AF. 
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